Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML
Phase I Clinical Trial
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)